Trabectedin: the evidence for its place in therapy in the treatment of soft tissue sarcoma | Zendy

Thornton | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Trabectedin: the evidence for its place in therapy in the treatment of soft tissue sarcoma

Author(s) -

Thornton

Publication year - 2009

Publication title -

core evidence

Language(s) - English

Resource type - Journals

eISSN - 1555-175X

pISSN - 1555-1741

DOI - 10.2147/ce.s5993

Subject(s) - trabectedin , soft tissue sarcoma , medicine , liposarcoma , sarcoma , oncology , soft tissue , ifosfamide , clinical endpoint , doxorubicin , clinical trial , surgery , chemotherapy , pathology , etoposide

Soft tissue sarcoma accounts for less than 1% of all malignant neoplasms and is comprised of a very heterogeneous group of tumors with over 50 different subtypes. Due to its diversity and rarity, developing new therapeutics has been difficult, at best. The standard of care in the treatment of advanced and metastatic disease over the last 30 years has been doxorubicin and ifosfamide, either alone or in combination. There has been significant focus on developing new therapeutics to treat primary and metastatic disease. Trabectedin (ecteinascidin-743) is a tetrahydroiso-quinoline alkaloid which has been evaluated in the treatment of metastatic soft tissue sarcoma.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research